1. Home
  2. FLUX vs BIVI Comparison

FLUX vs BIVI Comparison

Compare FLUX & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flux Power Holdings Inc.

FLUX

Flux Power Holdings Inc.

HOLD

Current Price

$0.65

Market Cap

14.3M

Sector

Miscellaneous

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.43

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLUX
BIVI
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.3M
13.3M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
FLUX
BIVI
Price
$0.65
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
84.9K
229.4K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
N/A
N/A
Revenue
$9,317,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.01
N/A
P/E Ratio
N/A
N/A
Revenue Growth
126.25
N/A
52 Week Low
$0.66
$1.06
52 Week High
$7.55
$8.34

Technical Indicators

Market Signals
Indicator
FLUX
BIVI
Relative Strength Index (RSI) 31.72 38.88
Support Level N/A $1.22
Resistance Level $1.18 $1.51
Average True Range (ATR) 0.08 0.24
MACD -0.01 -0.07
Stochastic Oscillator 7.14 12.12

Price Performance

Historical Comparison
FLUX
BIVI

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: